Collectively, these findings underscore the potent anti-inflammatory potential of MV-DDSs, which act through the precise modulation of key signaling pathways such as NF-κB and NLRP3, offering a promising therapeutic strategy for the treatment of IBD. The gene discussed is NLRP3; the disease is inflammatory bowel disease.